Medicus Pharma (NASDAQ: MDCX) has announced it will focus SkinJect development exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further development in sporadic/nodular basal cell carcinoma.
According to Medicus, the decision builds on the company’s portfolio strategy announced earlier this month, under which it is concentrating resources on programs offering the most compelling risk-adjusted opportunity.
In a statement, Dr. Raza Bokhari, CEO of Medicus, commented, “Our September 8 strategic update established a clear principle for Medicus: we intend to concentrate capital where focused clinical development can create the greatest risk-adjusted value. Today’s decision applies that discipline directly to SkinJect.”
